Glutamate Carboxypeptidase 2 Market
Glutamate Carboxypeptidase 2 Market Size, Share and Trends Analysis Report, By Type (INO-5150, E-2072, and Others), and By Application (Prostate Cancer, Neuropathic Pain, Cognitive Impairment, and Glioblastoma Multiforme), Forecast Period (2026-2035)
Industry Overview
Global glutamate carboxypeptidase 2 market was valued at $2.7 billion in 2025 and is projected to reach $7.0 billion by 2035, growing at a CAGR of 10.0% from 2026 to 2035. The global market is experiencing steady expansion, supported by the increasing commercialization of specialized therapeutic and diagnostic solutions. Advancements in targeted treatment approaches have strengthened clinical adoption across key healthcare systems. Growing regulatory approvals and improved reimbursement frameworks are further enabling market penetration. In addition, investments in advanced manufacturing capabilities are enhancing product availability and scalability. Strategic collaborations among industry participants are also accelerating innovation and distribution efficiency. Collectively, these factors are contributing to sustained and measurable market growth over the forecast period.
Market Dynamics
Rising Adoption of Targeted Diagnostic and Therapeutic Solutions
The market is witnessing a notable shift toward highly targeted diagnostic and therapeutic approaches, driven by the need for improved clinical precision and patient outcomes. Advances in molecular imaging and targeted treatment modalities are enabling earlier detection and more effective disease management. Healthcare providers are increasingly prioritizing solutions that offer specificity and reduced off-target effects. This transition is further supported by evolving clinical guidelines and growing physician awareness. In addition, enhanced diagnostic accuracy is contributing to better treatment planning and monitoring. As a result, demand for such specialized solutions continues to strengthen across major healthcare markets.
Expansion of Production Capabilities and Global Distribution Networks
Industry participants are actively investing in expanding production infrastructure and strengthening global distribution capabilities to meet rising demand. The development of advanced manufacturing facilities is improving supply reliability and scalability. At the same time, companies are forming strategic partnerships to optimize logistics and ensure timely product availability. Increasing focus on regional production hubs is also helping to address supply chain constraints. Regulatory support in key markets is facilitating faster approvals and market access. These developments are collectively enhancing the efficiency and reach of product distribution worldwide.
Market Segmentation
- Based on the type, the market is segmented into INO-5150, E-2072, and others.
- Based on the application, the market is segmented into prostate cancer, neuropathic pain, cognitive impairment, and glioblastoma multiforme.
Prostate Cancer Segment to Lead the Market with the Largest Share
The prostate cancer segment continues to hold a leading position due to its well-established diagnostic pathways and increasing reliance on targeted treatment approaches. Clinical adoption has been supported by consistent improvements in detection accuracy and treatment monitoring, allowing for more personalized care strategies. Healthcare systems are prioritizing solutions that enable early identification and precise intervention, which has reinforced demand within this segment. In addition, favorable reimbursement structures in key regions have contributed to wider accessibility. Ongoing clinical validation and physician familiarity further strengthen its position. As a result, this segment sustains a dominant share within the overall market landscape.
E-2072: A Key Segment in Market Growth
E-2072 is emerging as a fast-growing segment, driven by increasing research interest and its potential to address unmet clinical needs. Advancements in targeted mechanisms and ongoing evaluations are supporting its progression toward broader applicability. Industry participants are directing investments toward development and validation efforts to strengthen their commercial prospects. The segment is also benefiting from a growing focus on precision-based therapeutic approaches. As clinical understanding expands, its potential use cases are expected to widen. These factors collectively position E-2072 as a segment with notable growth potential in the coming years.
Regional Outlook
The global glutamate carboxypeptidase 2 market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Region Dominates the Market with Major Share
North America continues to account for a significant share of the global market, supported by a well-established healthcare infrastructure and strong adoption of advanced diagnostic and therapeutic solutions. The presence of major industry participants, along with early access to innovative products, has strengthened regional leadership. Favorable reimbursement policies and streamlined regulatory pathways have further encouraged clinical uptake. In addition, ongoing investments in research and development contribute to continuous product advancement. High awareness among healthcare professionals and patients also supports consistent demand. These factors collectively sustain North America’s leading position in the market.
Asia-Pacific to Emerge as the Fastest-Growing Region
Asia-Pacific is expected to register the fastest growth over the forecast period, driven by improving healthcare infrastructure and increasing access to advanced treatment options. Rising healthcare expenditure and expanding patient populations are creating favorable conditions for market expansion. Governments across the region are actively supporting modernization initiatives, which are enhancing diagnostic and treatment capabilities. In addition, growing investments by global and regional players are strengthening distribution networks and local manufacturing capacity. Increasing awareness and adoption of advanced medical technologies are further accelerating growth. As a result, the Asia-Pacific is positioned to become a key growth engine for the market.
Market Players Outlook
The major companies operating in the global glutamate carboxypeptidase 2 market include Novartis AG, Lantheus Holdings, Inc., Telix Pharmaceuticals Ltd., GE HealthCare Technologies Inc., and Siemens Healthineers AG, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Development
- In March 2025, Novartis AG received U.S. Food and Drug Administration approval for an expanded indication of its PSMA-targeted radioligand therapy Pluvicto, enabling its use in earlier-stage prostate cancer patients and significantly increasing the eligible treatment population. This regulatory expansion strengthens the commercial scope of GCPII-targeted therapeutics by broadening clinical adoption and market access. The approval was supported by Phase III trial data demonstrating improved progression-free survival outcomes.
The Report Covers
- Market value data analysis for 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global glutamate carboxypeptidase 2 market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Glutamate Carboxypeptidase 2 Market Sales Analysis – Type | Application | ($ Million)
- Glutamate Carboxypeptidase 2 Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Glutamate Carboxypeptidase 2 Industry Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Glutamate Carboxypeptidase 2 Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Glutamate Carboxypeptidase 2 Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Glutamate Carboxypeptidase 2 Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Glutamate Carboxypeptidase 2 Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Glutamate Carboxypeptidase 2 Market Revenue and Share by Manufacturers
- Glutamate Carboxypeptidase 2 Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- GE HealthCare Technologies Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Lantheus Holdings, Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Novartis AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Siemens Healthineers AG
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Telix Pharmaceuticals Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- GE HealthCare Technologies Inc.
- Key Company Analysis
- Global Glutamate Carboxypeptidase 2 Market Sales Analysis by Type ($ Million)
- INO-5150
- E-2072
- Others
- Global Glutamate Carboxypeptidase 2 Market Sales Analysis by Application ($ Million)
- Prostate Cancer
- Neuropathic Pain
- Cognitive Impairment
- Glioblastoma Multiforme
- Regional Analysis
- North American Glutamate Carboxypeptidase 2 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Glutamate Carboxypeptidase 2 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Glutamate Carboxypeptidase 2 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Others)
- Rest of Asia-Pacific
- Rest of the World Glutamate Carboxypeptidase 2 Market Sales Analysis – Type | Application | Country ($ Million)
- Macroeconomic Factors for the Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- ABX Advanced Biochemical Compounds GmbH
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bayer AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Blue Earth Diagnostics Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Bracco Imaging S.p.A.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cardinal Health, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Clarity Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Curium Holding France SAS
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GE HealthCare Technologies Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Ion Beam Applications SA
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Isotopia Molecular Imaging Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- ITM Isotope Technologies Munich SE
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Lantheus Holdings, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Mallinckrodt Pharmaceuticals plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Nordion (Canada) Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- RadioMedix, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Siemens Healthineers AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Telix Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Triad Isotopes, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- ABX Advanced Biochemical Compounds GmbH
1. Global Glutamate Carboxypeptidase 2 Market Research And Analysis By Type, 2025-2035 ($ Million)
2. Global INO-5150 Glutamate Carboxypeptidase 2 Market Research And Analysis By Region, 2025-2035 ($ Million)
3. Global E-2072 Glutamate Carboxypeptidase 2 Market Research And Analysis By Region, 2025-2035 ($ Million)
4. Global Other Type Glutamate Carboxypeptidase 2 Market Research And Analysis By Region, 2025-2035 ($ Million)
5. Global Glutamate Carboxypeptidase 2 Market Research And Analysis By Application, 2025-2035 ($ Million)
6. Global Glutamate Carboxypeptidase 2 For Prostate Cancer Market Research And Analysis By Region, 2025-2035 ($ Million)
7. Global Glutamate Carboxypeptidase 2 For Neuropathic Pain Market Research And Analysis By Region, 2025-2035 ($ Million)
8. Global Glutamate Carboxypeptidase 2 For Cognitive Impairment Market Research And Analysis By Region, 2025-2035 ($ Million)
9. Global Glutamate Carboxypeptidase 2 For Glioblastoma Multiforme Market Research And Analysis By Region, 2025-2035 ($ Million)
10. Global Glutamate Carboxypeptidase 2 Market Research And Analysis By Geography, 2025-2035 ($ Million)
11. North American Glutamate Carboxypeptidase 2 Market Research And Analysis By Country, 2025-2035 ($ Million)
12. North American Glutamate Carboxypeptidase 2 Market Research And Analysis By Type, 2025-2035 ($ Million)
13. North American Glutamate Carboxypeptidase 2 Market Research And Analysis By Application, 2025-2035 ($ Million)
14. European Glutamate Carboxypeptidase 2 Market Research And Analysis By Country, 2025-2035 ($ Million)
15. European Glutamate Carboxypeptidase 2 Market Research And Analysis By Type, 2025-2035 ($ Million)
16. European Glutamate Carboxypeptidase 2 Market Research And Analysis By Application, 2025-2035 ($ Million)
17. Asia-Pacific Glutamate Carboxypeptidase 2 Market Research And Analysis By Country, 2025-2035 ($ Million)
18. Asia-Pacific Glutamate Carboxypeptidase 2 Market Research And Analysis By Type, 2025-2035 ($ Million)
19. Asia-Pacific Glutamate Carboxypeptidase 2 Market Research And Analysis By Application, 2025-2035 ($ Million)
20. Rest Of The World Glutamate Carboxypeptidase 2 Market Research And Analysis By Country, 2025-2035 ($ Million)
21. Rest Of The World Glutamate Carboxypeptidase 2 Market Research And Analysis By Type, 2025-2035 ($ Million)
22. Rest Of The World Glutamate Carboxypeptidase 2 Market Research And Analysis By Application, 2025-2035 ($ Million)
1. Global Glutamate Carboxypeptidase 2 Market Share By Type, 2025 Vs 2035 (%)
2. Global INO-5150 Glutamate Carboxypeptidase 2 Market Share By Region, 2025 Vs 2035 (%)
3. Global E-2072 Glutamate Carboxypeptidase 2 Market Share By Region, 2025 Vs 2035 (%)
4. Global Other Type Glutamate Carboxypeptidase 2 Market Share By Region, 2025 Vs 2035 (%)
5. Global Glutamate Carboxypeptidase 2 Market Share By Application, 2025 Vs 2035 (%)
6. Global Glutamate Carboxypeptidase 2 For Prostate Cancer Market Share By Region, 2025 Vs 2035 (%)
7. Global Glutamate Carboxypeptidase 2 For Neuropathic Pain Market Share By Region, 2025 Vs 2035 (%)
8. Global Glutamate Carboxypeptidase 2 For Cognitive Impairment Market Share By Region, 2025 Vs 2035 (%)
9. Global Glutamate Carboxypeptidase 2 For Glioblastoma Multiforme Market Share By Region, 2025 Vs 2035 (%)
10. Global Glutamate Carboxypeptidase 2 Market Share By Region, 2025 Vs 2035 (%)
11. US Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
12. Canada Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
13. UK Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
14. France Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
15. Germany Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
16. Italy Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
17. Spain Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
18. Russia Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
19. Rest Of Europe Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
20. India Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
21. China Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
22. Japan Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
23. South Korea Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
24. ASEAN Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
25. Australia and New Zealand Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
26. Rest Of Asia-Pacific Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
27. Latin America Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
28. Middle East And Africa Glutamate Carboxypeptidase 2 Market Size, 2025-2035 ($ Million)
- Printable version
- No restriction to number of users within the company
